Houston Holmes

3.0k total citations
39 papers, 540 citations indexed

About

Houston Holmes is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Houston Holmes has authored 39 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 9 papers in Immunology. Recurrent topics in Houston Holmes's work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Houston Holmes is often cited by papers focused on CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Houston Holmes collaborates with scholars based in United States, Netherlands and France. Houston Holmes's co-authors include William R. Drobyski, Patrick G. Beatty, Sergio Giralt, John E. Levine, Rodrigo Martino, Thomas Braun, Mary M. Horowitz, Robert H. Collins, Matthew Johnson and Kenneth Cornetta and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Houston Holmes

38 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Houston Holmes United States	12	319	202	146	119	88	39	540
Paul Maciocia United Kingdom	9	378 1.2×	85 0.4×	121 0.8×	153 1.3×	131 1.5×	23	504
Christine Dehner United States	11	402 1.3×	153 0.8×	152 1.0×	112 0.9×	88 1.0×	19	520
Alessandro Crotta United States	7	273 0.9×	99 0.5×	121 0.8×	55 0.5×	48 0.5×	26	369
Noemi Mergen Germany	8	503 1.6×	195 1.0×	186 1.3×	135 1.1×	57 0.6×	13	687
Alessandro Previtali United States	7	257 0.8×	101 0.5×	111 0.8×	76 0.6×	84 1.0×	18	374
Hien Liu United States	11	449 1.4×	144 0.7×	153 1.0×	67 0.6×	156 1.8×	62	594
Jörg Faber Germany	11	192 0.6×	109 0.5×	31 0.2×	106 0.9×	144 1.6×	31	466
Gloria Iacoboni Spain	16	588 1.8×	73 0.4×	294 2.0×	111 0.9×	102 1.2×	65	730
Naomi Porret Switzerland	11	157 0.5×	199 1.0×	48 0.3×	39 0.3×	130 1.5×	41	440
Sameh Gaballa United States	12	169 0.5×	269 1.3×	87 0.6×	98 0.8×	68 0.8×	55	413

Countries citing papers authored by Houston Holmes

Since Specialization

Citations

This map shows the geographic impact of Houston Holmes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Houston Holmes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Houston Holmes more than expected).

Fields of papers citing papers by Houston Holmes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Houston Holmes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Houston Holmes. The network helps show where Houston Holmes may publish in the future.

Co-authorship network of co-authors of Houston Holmes

This figure shows the co-authorship network connecting the top 25 collaborators of Houston Holmes. A scholar is included among the top collaborators of Houston Holmes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Houston Holmes. Houston Holmes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Boyu, Loretta J. Nastoupil, Houston Holmes, et al.. (2024). A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.. Journal of Clinical Oncology. 42(16_suppl). 7025–7025. 9 indexed citations

Khanal, Rashmi, Amitkumar Mehta, Joseph Maly, et al.. (2023). AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7529–7529. 3 indexed citations

Berdeja, Jesús G., Thomas G. Martin, Adriana Rossi, et al.. (2023). A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).. Journal of Clinical Oncology. 41(16_suppl). TPS8063–TPS8063. 10 indexed citations

Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2022). Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies. Blood. 140(Supplement 1). 3655–3657. 2 indexed citations

Neelapu, Sattva S., Mehdi Hamadani, David B. Miklos, et al.. (2022). A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.. Journal of Clinical Oncology. 40(16_suppl). 7509–7509. 28 indexed citations

Khanal, Rashmi, Jennifer N. Saultz, Umar Farooq, et al.. (2022). Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 140(Supplement 1). 12742–12743. 1 indexed citations

Neelapu, Sattva S., Don A. Stevens, Mehdi Hamadani, et al.. (2022). A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies. Blood. 140(Supplement 1). 4617–4619. 23 indexed citations

Wang, Michael, John M. Rossi, Javier Muñoz, et al.. (2021). Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial. Transplantation and Cellular Therapy. 27(3). S341–S342. 2 indexed citations

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2020). Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 43–45. 43 indexed citations

10.

Wang, Michael, Javier Muñoz, André Goy, et al.. (2020). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. Biology of Blood and Marrow Transplantation. 26(3). S1–S1. 6 indexed citations

11.

Wang, Michael, Javier Muñoz, André Goy, et al.. (2019). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Blood. 134(Supplement_1). 754–754. 18 indexed citations

12.

Benson, Don M., Houston Holmes, Parameswaran Hari, et al.. (2018). A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma. Blood. 132(Supplement 1). 1997–1997. 6 indexed citations

13.

Shah, Bijal, Olalekan O. Oluwole, Maria R. Baer, et al.. (2018). KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3. Clinical Lymphoma Myeloma & Leukemia. 18. S184–S184. 1 indexed citations

14.

Shah, Bijal, Olalekan O. Oluwole, Maria R. Baer, et al.. (2018). Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).. Journal of Clinical Oncology. 36(15_suppl). 7006–7006. 8 indexed citations

15.

Holmes, Houston, et al.. (2017). Breast Implant-Associated Anaplastic Large Cell Lymphoma. Baylor University Medical Center Proceedings. 30(4). 441–442. 5 indexed citations

16.

Casulo, Carla, Eric D. Jacobsen, Koen Van Eygen, et al.. (2016). Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.. Journal of Clinical Oncology. 34(15_suppl). e19052–e19052. 5 indexed citations

17.

Shiller, S. Michelle, Arthur W. Zieske, Houston Holmes, et al.. (2011). CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. Cancer Genetics. 204(3). 162–164. 7 indexed citations

18.

Holmes, Houston, et al.. (2009). Clinical Strategies for Supporting the Untransfusable Hemorrhaging Patient. Baylor University Medical Center Proceedings. 22(4). 316–320. 5 indexed citations

19.

Agura, Edward, R.B. Berryman, Barry Cooper, et al.. (2006). Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.. Blood. 108(11). 1951–1951. 9 indexed citations

20.

Konkle, Barbara A., et al.. (2003). Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 43(3). 390–394. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact